Developing Oncolytic Viruses for the Treatment of Cervical Cancer

• Published in: Cells (Basel, Switzerland) Switzerland), 2023-07, Vol.12 (14), p.1838
• Main Authors: Kalafati, Eleni, Drakopoulou, Ekati, Anagnou, Nicholas P, Pappa, Kalliopi I
• Format: Article
• Language: English
• Subjects: Adenoviruses; Angiogenesis; cancer immunotherapy; Cancer therapies; Care and treatment; Cell cycle; Cell growth; Cervical cancer; Clinical trials; Cytotoxicity; FDA approval; Human papillomavirus; Immune system; Immunotherapy; innate immunity; Malignancy; Medical prognosis; Medical screening; Metastases; Metastasis; Oncolysis; oncolytic viruses; Prevention; Proteins; Quality of life; Review; Tumors; viral vectors; virotherapy; Viruses
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells12141838

Cervical cancer represents one of the most important malignancies among women worldwide. Current therapeutic approaches for cervical cancer are reported not only to be inadequate for metastatic cervical cancer, but are also considered as cytotoxic for several patients leading to serious side effects, which can have negative implications on the quality of life of women. Therefore, there is an urgent need for the development of innovative and effective treatment options. Oncolytic viruses can eventually become effective biological agents, since they preferentially infect and kill cancer cells, while leaving the normal tissue unaffected. Moreover, they are also able to leverage the host immune system response to limit tumor growth. This review aims to systematically describe and discuss the different types of oncolytic viruses generated for targeting cervical cancer cells, as well as the outcome of the combination of virotherapy with conventional therapies. Although many preclinical studies have evaluated the therapeutic efficacy of oncolytic viruses in cervical cancer, the number of clinical trials so far is limited, while their oncolytic properties are currently being tested in clinical trials for the treatment of other malignancies.